Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications
- 15 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Environmental Science and Pollution Research
- Vol. 28 (30), 40431-40444
- https://doi.org/10.1007/s11356-020-12200-1
Abstract
The outbreak of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the entire world with its infectious spread and mortality rate. The severe cases of coronavirus disease 2019 (COVID-19) are characterized by hypoxia and acute respiratory distress syndrome. In the absence of any specific treatment, just the preventive and supportive care options are available. Therefore, much focus is given to assess the available therapeutic options not only to avoid acute respiratory failure and hypoxia but also to reduce the viral load to control the severity of the disease. The antimalarial drug hydroxychloroquine (HCQ) is among the much-discussed drugs for the treatment and management of COVID-19 patients. This article reviews the therapeutic potential of HCQ in the treatment of COVID-19 based on the available in vitro and clinical evidence, current status of registered HCQ-based clinical trials investigating therapeutic options for COVID-19, and environmental implications of HCQ.This publication has 112 references indexed in Scilit:
- Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal modelCell Research, 2012
- Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine RetinopathyOphthalmology, 2011
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitisRespiratory Research, 2010
- Hydroxychloroquine overdose: case report and recommendations for managementEuropean Journal of Emergency Medicine, 2008
- Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral ActivitiesJournal of Medicinal Chemistry, 2006
- Vitamin C and SARS coronavirusJournal of Antimicrobial Chemotherapy, 2003
- Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical propertiesJournal of Antimicrobial Chemotherapy, 2003
- Drug Interaction of Chloroquine with CiclosporinNephron, 1992
- Effect of Chloroquine Adsorption on Acid Reactivity of Magnesium TrisilicateJournal of Pharmaceutical Sciences, 1977